Skip to main content

Table 1 Baseline demographic and clinical characteristics, by sex (n = 2736)

From: Social functioning outcomes in men and women receiving medication-assisted treatment for opioid use disorder

Characteristic Women Men p
Sex (n, % of total) 1192, 44% 1544, 56%  
Age in years (mean ± SD, min–max) 37.58 ± 10.64, 18–69 39.12 ± 11.14, 17–76 < 0.001***
Type of MAT (n, % of total on Methadone) 1008, 85% 1313, 85% 0.731
Type of MAT (n, % of total on Buprenorphine) 184, 15% 231, 15% 0.731
Methadone dose; mg/day
(mean ± SD, min–max)
68.30 ± 40.13, 0–320 73.23 ± 45.05, 2–405 0.006**
Buprenorphine dose; mg/day
(mean ± SD, min–max)
12.31 ± 7.24, 1–40 11.82 ± 6.74, 0–32 0.478
Years on MAT (median, IQR, min–max) 2, 4.71, 0–40 2, 4.42, 0–33 0.432
New to MAT; < 1 year (n, % of total) 436, 43% 564, 43% 0.904
Percentage of opioid-positive urine drug screens
(mean ± SD)
18.15% ± 26.49 19.42% ± 27.88 0.228
Physical symptoms (mean score ± SD) 16.50 ± 7.70 13.62 ± 7.74 < 0.001***
Psychological symptoms (mean score ± SD) 14.01 ± 9.55 11.37 ± 8.64 < 0.001***
Unemployed (n, % of total) 882, 74% 902, 58% < 0.001***
Any crime (n, % of total) 92, 8% 177, 11% 0.001**
Episodes of crime per month, in those who commit crime (median, IQR) 4, 25 9, 88 0.032*
Any conflict (n, % of total) 550, 46% 533, 35% < 0.001***
Percentage of contact time spent in conflict, in those reporting conflict (median, IQR) 8.45%, 26.10% 7.69%, 20.20% 0.596
  1. *p < 0.05
  2. **p < 0.01
  3. ***p < 0.001
  4. Min–max = minimum–maximum, MAT = medication-assisted treatment, SD = standard deviation, IQR = interquartile range